MRSA is caused by a strain of staph bacteria that's become resistant to most antibiotics. It's life-threatening and is often found in hospitals and other health care settings.
The new drug, called Dalvance, is taken intravenously. The drug is only approved for use in adults, according to the Chicago-based company that markets the drug, Durata Therapeutics.
What makes it different from other MRSA antibiotics is the way it was approved.
This is the first drug labeled by the FDA as a Qualified Infectious Disease Product. QIDP is part of a program that the administration hopes will encourage drug companies to develop new drugs like Dalvance that will fight the epidemic of antibiotic-resistant infections. READ MORE
Gee, I wonder if the FDA will ever approve silver :) beinki